MGC
Pharmaceuticals Ltd
Compliance Release - Application for Admission to
Trading
13
February 2024
ASX, LSE:
MXC
MGC
Pharmaceuticals Ltd ("MGC
Pharma" or
the "Company") is applying for
admission to the Financial Conduct Authority's Official List and to
trading on the Main Market of London Stock Exchange plc
("Admission") of 283,150
fully paid ordinary shares ("Shares") previously issued by MGC
Pharma. Admission of the Shares is expected to take place at 8:00am
(GMT) on 19 February 2024.
Details of the 283,150 Shares are as
follows:
· 1,600
Shares issued upon the conversion of securities granted under the
Company's Employee Share Scheme;
· 43,692
Shares issued to suppliers of the Company in lieu of cash
settlement;
· 107,483 shares issued to employees under the Company's
Employee Share Scheme; and
· 130,375 shares issued to investors pursuant to a capital
raising that took place in 2023.
The Shares have already been issued
and quoted on the ASX and application for Admission will not affect
the Total Voting Rights in the Company. At the date of this
announcement, the Company has 43,851,631 Shares in issue, each with
one voting right. Therefore, the Company's total number of Shares
in issue and voting rights will be 43,851,631 and this figure may
be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the FCA's Disclosure Guidance and Transparency Rules.
-Ends-
Authorised for release by the Managing Director, for further
information please contact:
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC,
ASX: MXC) is a prominent European pharmaceutical company with a
strong commitment to creating accessible and ethically produced
cutting-edge medicines. Our approach combines in-house research
with innovative technologies, all aimed at discovering and
producing treatments for currently unmet medical
conditions.
The company's founders and executives
are distinguished figures in the global pharmaceutical industry.
Our central business strategy revolves around the development and
supply of innovative medicines, responding to the increasing demand
in the medical markets of Europe, North America, and
Australasia.
MGC Pharma maintains a robust
development pipeline that addresses two prevalent medical
conditions, with additional products currently in the developmental
stages. We've established strategic partnerships with renowned
institutions and academia, fostering the optimization of our
medicines' development. These medicines are produced in our EU-GMP
Certified manufacturing facilities, ensuring the highest quality
standards.
With a growing patient base in key
regions like the USA, UK, Australia, and Ireland, MGC Pharma has
also built a global distribution network through a wide-reaching
group of commercial partners. This extensive network places us in a
prime position to supply the global market effectively.
Follow us through our social media
channels:
LinkedIn: MGC Pharmaceuticals
Ltd.
Twitter: @MGC_Pharma
Facebook:
@mgcpharmaceuticals
Instagram: @mgc_pharma